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Abstract: Nanoparticle research and development for pharmaceuticals is a challenging task in the
era of personalized medicine. Specialized and increased patient expectations and requirements
for proper therapy adherence, as well as sustainable environment safety and toxicology topics
raise the necessity of well designed, advanced and smart drug delivery systems on the market.
These stakeholder expectations and social responsibility of pharma sector open the space and call
new methods on the floor for new strategic development tools, like Quality by Design (QbD)
thinking. The extended model, namely the R&D QbD proved to be useful in case of complex and/or
high risk/expectations containing or aiming developments. This is the case when we formulate
polymeric micelles as promising nanotherapeutics; the risk assessment and knowledge-based quality
targeted QbD approach provides a promising tool to support the development process. Based on
risk assessment, many factors pose great risk in the manufacturing process and affect the quality,
efficacy and safety profile. The quality-driven strategic development pathway, based on deep prior
knowledge and an involving iterative risk estimation and management phases has proven to be an
adequate tool, being able to handle their sensitive stability issues and make them efficient therapeutic
aids in case of several diseases.
Keywords: Quality by Design; polymeric micelle; risk assessment; quality management; knowledge
phase; preformulation space
1. Introduction
Research and development (R&D) has changed enormously in recent decades and
leaders of pharma companies are in the midst of unprecedented change. With the increased
prevalence of chronic pulmonary diseases due to pollution, vascular and neurological dis-
eases from obesity and the aging population pyramid and, last but not least, the occurrence
of pandemics such as COVID-19 or Ebola accelerate pharmaceutical manufacturing and
research processes that must be adhered to strict quality conditions. A newly manufactured
and market-placed medicine has to face obstacles for the industry players. Changes in
consumer attitudes, cybersecurity threats, rapid advances in technology, non-adequate
return on innovation and competition from companies in emerging economies are several
of them [1,2]. In the 21st century, a novel quality assurance approach, Quality by Design
(QbD)), appeared, oriented towards quality of the product and the improved patient appli-
cability during therapeutic use. Quality, safety and efficacy are the three cornerstones of
the QbD approach, which is built around starting from preformulation studies all the way
to the patient’s own use [3,4].
With the development of nano drug delivery systems (nanoDDS), the previous quality
assurance systems were no longer sufficient, which also supports the QbD method based
on quality, knowledge and risk assessment [5]. Lipid-, polymer-based or other nanoDDSs
all require a specific regulatory environment [6,7]. On the one hand, the reason for this
is to be found in the production process, as conventional production line equipment is
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not necessarily suitable for the production of these products besides the need of special
conditions and constant control. The opportunity is there in the hands of all developers to
apply this method and in the course of our research group, the existence was proven on
many occasions for nanoDDSs, such as liposomes [8], polymeric micelles [9] and human
serum albumin nanoparticles [10]. On the other hand, safety must also be proven, as an
increase in efficacy is expected due to the advanced properties of the systems, but in the
case of improperly optimized preparations, it can lead to nanotoxicity and severe side
effects [11,12].
Polymeric micelles are self-assembling association colloidal systems composed of
amphiphilic copolymers capable of entrapping hydrophobic drugs [13]. They have a
number of advantages, perhaps the most important of which is the increase in water
solubility, along with a reduction in particle size. Together, these two factors contribute to a
more favourable pharmacokinetic profile and to the incorporation of certain poorly soluble
or penetrating active pharmaceutical ingredients (APIs) into a liquid dosage form [14].
The physical stability of the polymeric micelles proves to be adequate and they are able to
maintain their particle size even during the circulation time in the bloodstream. In addition
to administration by alternative administration routes, they show increased resistance to the
body’s metabolic effects, which is also important for maintaining the active, effective form
of the API [15]. For safety and quality assured development, every developer must consider
all possible outcomes before, in between and after the preparation of nanotherapeutics,
which needs a holistic and systematic knowledge space-based development [16]. As
mentioned, the leaders of pharma industry must create innovative dosage forms in order
to stand a chance in the global market. To achieve this, polymeric micelles are an excellent
solution. Compared to liquid formulations, these nanosized systems have the higher
ground when talking about decrease of dosage strength; therefore, the occurrence of side
effects, the ability to offer higher permeability and flux values across biological membranes
and, last but not least, the pleasing carrier integrity through the circulation in the body.
The aim of this research article is to collect and evaluate the critical parameters
affecting polymeric micelles as promising drug delivery systems as part of the extension of
QbD to the early development phase of pharmaceutical R&D processes [17]. This article
develops the formulation space through the adaptation of literature date into exact quality-
influencing factors. Based on our previous experience from formulation studies in the field
of nanotechnology and polymeric micelles supplemented by literature data, quantified risk
severities based on this systematic summary was calculated in order to help and encourage
professionals in the pharmaceutical field to apply QbD in the development processes. Later,
described possible Quality Target Product Profile (QTPP) and Critical Quality Attributes
(CQAs) were collected and an extensive risk assessment (RA) was performed on them. The
Critical Process Parameters (CPPs) and Critical Material Attributes (CMAs) went through
a RA also and because many formulation methods exist in the development of polymeric
micelles, these methods were evaluated individually.
2. Materials and Methods
2.1. General Methodology of QbD
Based on specified guidelines of the International Council of Harmonisation of Techni-
cal Requirements for Pharmaceuticals for Human Use [18–20], the QbD procedure followed
the following steps (Figure 1).




Figure 1. Schematics for the Quality by Design methodology. 
At first, QTPPs were determined representing the desired quality characteristics of a 
finalized API-loaded polymeric micelle. The ICH guidelines state the mandatory QTPP 
elements such as indication, route of administration etc. and other safety and efficacy in-
fluencing factors were taken into account [18]. CQAs, CPPs and CMAs were selected in 
the next step. CQAs are physicochemical, biological or microbiological characteristics 
which should be controlled in an appropriate range to ensure product quality. CPPs and 
CMAs are related to the production of the product, which should be monitored [18–20]. 
Based on the collection process, a risk assessment was evaluated [20]. Data from the liter-
ature were collected using journal publishers’ search engines. 
2.2. Risk Assessment Procedure 
As QbD is a knowledge- and risk assessment-focused approach, qualitative and 
quantitative risk factors, expressed as severity scores, must be presented [17]. LeanQbD 
Software (QbD Works LLC, Fremont, CA, USA) was used for the RA procedure. At first, 
an interdependence rating amongst the QTPPs and the CQAs and the CQAs and the CPPs 
was performed. A three-level scale was used to describe the relation between these pa-
rameters: each relation was assigned with a “high” (H), “medium” (M) or “low” (L) at-
tributive. The decision of assignment was performed based on numerous aspects includ-
ing: occurrence of the risk factor during formulation and/or final product development 
phase; controllability of the factor; whether the factor can be eliminated or can it be fixed 
at a certain value without affecting quality; detectability. The description of relations had 
the fundamental basis of how closely the factors are related and data from the collected 
literature, in addition to the regulatory aspects of a joint MHLW/EMA reflection paper on 
the development of block copolymer micelle medicinal products [21]. Using the software, 
these qualitative relations were the basis of calculating the severity scores. As the output 
Figure 1. Schematics for the Quality by Design methodology.
At first, QTPPs were determined representing the desired quality characteristics of a
finalized API-loaded polymeric micelle. The ICH guidelines state the mandatory QTPP
elements such as indication, route of administration etc. and other safety and efficacy
influencing factors were taken into account [18]. CQAs, CPPs and CMAs were selected
in the next step. CQAs are physicochemical, biological or microbiological characteristics
which should be controlled in an appropriate range to ensure product quality. CPPs and
CMAs are related to the production of the product, which should be monitored [18–20].
Based on the collection process, a risk assessment was evaluated [20]. Data from the
literature were collected using journal publishers’ search engines.
2.2. Risk Assessment Procedure
As QbD is a knowledge- and risk assessment-focused approach, qualitative and
quantitative risk factors, expressed as severity scores, must be presented [17]. LeanQbD
Software (QbD Works LLC, Fremont, CA, USA) was used for the RA procedure. At first, an
interdependence rating amongst the QTPPs and the CQAs and the CQAs and the CPPs was
performed. A three-level scale was used to describe the relation between these parameters:
each relation was assigned with a “high” (H), “medium” (M) or “low” (L) attributive. The
decision of assignment was performed based on numerous aspects including: occurrence of
the risk factor during formulation and/or final product development phase; controllability
of the factor; whether the factor can be eliminated or can it be fixed at a certain value
without affecting quality; detectability. The description of relations had the fundamental
basis of w closely the factors are rel ted and data from the c llected literature, in addition
to the regulat ry aspects of a joint MHLW/EMA reflection paper on the development of
block copolymer micelle medicinal products [21]. Using th software, these qualitative
relations were the basis of a culating the severity cores. As the output of the RA, Pareto
diagrams were generated, presenting numeric data and ranking of the CQAs and the CPPs
representing the potential impact on the final product [22].
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3. Results
3.1. Collection of QTPPs for Polymeric Micelle Development
The definition of QTPPs is the first major step in the development of nanoDDS; in this
case, polymeric micelles. In addition to the mandatory elements of the ICH guidelines,
optional QTPPs can be defined, which mainly depends on the nature of the target product.
Defining the indication is of paramount importance. This QTPP is most often due to the
properties and previous application of the API. By forming a polymeric micelle formulation,
the indications in the previous SPCs can be also supplemented [23]. Achieving this plays
an important role mainly in immune and cancer therapy [24]. On the other hand, by
innovating the mode of application, the API can be delivered to biological spaces which
previous conventional formulations are not capable of. A particularly good example
of this is the delivery of non-steroidal anti-inflammatory drugs to the central nervous
system (CNS) for the treatment of neuroinflammation, in which case, conventional peroral
formulations do not or only a small extent can enter [25].
The patient population as QTPP is also a mandatory clarifying factor that can be
expand beyond the age associated with the general drug. The development into a liquid
dosage form is beneficial for the patient, as the product can be used even in case of
swallowing difficulty. This is especially important in pediatric and geriatric medication,
where patient experience is of paramount importance to improve therapy fidelity, the
so-called adherence [26]. Polymeric micelle formulations designed for a conventional route
of administration are aimed primarily to increase the bioavailability of products previously
authorized for that route. However, new development trends prefer alternative routes
of administration, of which the ophthalmic, topical and nasal delivery play the largest
role [27–29]. A significant number of active substances are able to exert their effect only at
certain point of action in the body, in the given indication. However, this does not mean that
their potential is not greater and nanoformulations are able to deliver APIs to new sites. Of
these, the intake of the drug into the CNS and cancer cells should be highlighted [30,31]. The
dosage strength of the formulation depends on many things: indication, API features and
the administration route. Manufacturers should clearly indicate the proposed dosage form
of the formulation because they have different stability and product quality in colloidal
solution, colloidal gelling system or freeze-dried form [14].
Physicochemical characteristics are common amongst QTPPs as well, depending on
the indication and the administration route. Most commonly, viscosity, osmolality, pH and
mucoadhesive properties are presented. The particle characteristics of polymeric micelles
include the particle size (expressed as Z-average), particle size distribution (expressed as
polydispersity index, PdI), zeta potential, encapsulation efficiency (EE%) and drug loading
(DL%). These are the factors that facilitate the implementation of the other QTPP elements.
They can also appear as CQAs, but in the scope of regulation of nanosystems, these factors
must be defined in the initial plan, as part of the basis of technological innovation lies in
their regulation [8,12].
The properties of the copolymers and the API determine the safety profile of the target
product the most. The main criterion for polymers is that they are biocompatible with
the human body and that, after their metabolism, the degradation products do not cause
harmful side effects [32]. Where necessary, sterility is also required, as well as the product
characteristics that allow the safe use of the dosage form and the administration route. The
stability of polymeric micelles can be approached in several ways. Stability in aqueous
solutions means a constant particle size after redispersion and a reduction in the tendency
to aggregate. In addition to the liquid form, it is also worth checking these parameters
during storage after freeze-drying [14]. Some copolymers are temperature and pH sensitive,
so it is important to know whether a particular product can provide the expected effect
under these factors. Changes in structure are expected after drug loading and which
are also critical parameters of product characteristics. The classification of solubility
among QTPPs is also a common case, as reducing redispersion time, improving solubility
rate and increasing wetting properties are also the goal in the production of polymeric
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micelles. This is closely related to drug release, such as QTPP, where different aims can be
achieved. Most commonly, the aim is the rapid onset of action, but in other cases, sustained
release with prolonged circulation time can be accomplished after modifying the polymeric
micelle structure [33,34]. Drug release is also influenced based on indication, the route of
administration and the API itself. Drug permeability is included as QTPP, aiming either to
enhance passive diffusion or the carrier-mediated active transport mechanisms [35]. The
described QTPPs are summarized in Table 1.
Table 1. Systematic collection of feasible QTPP elements for the development of polymeric mi-
celle nanoDDSs.
QTPP Element Details
indication general API-basedextension of general API-based
patient population paediatrics or geriatricsgeneral, API-based









freeze-dried powder for further reconstitution
viscosity based on indication and administration route
osmolality based on indication and administration route
pH based on indication and administration route
mucoadhesive properties based on indication and administration route
particle characteristics
particle size (Z-average)



















rapid onset of action
sustained release
prolonged circulation time
based on indication, administration route and API
drug permeability passive diffusion enhancementcarrier-mediated active transport enhancement
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3.2. How to Choose the Proper QTPP Elements for the Research Project?
When QbD comes to the fore as a tool to use in research, the first step is to gather
the QTPP elements; however, the question arises as to which ones are needed within the
general elements or whether another one could be added to the QbD setup. Many questions
must be answered in the beginning which will help the determination of QTPPs:
• With the formulation, do I change more than the physicochemical properties of the API?
• What would the final dosage form? What are the requirements for it?
• Is there something similar in the literature or on the market? What more can I add to
the formulation?
• Who should be the recipients of my formulation? What are the criteria for that target
population?
• Do I possess all the necessary tools in my experiments to validate my claims and to
characterize the nanocarrier?
• What is the chosen dosage strength and what pharmacokinetic changes can be ex-
pected? How do these changes affect the target population and do I need to make
adjustments?
• What can the polymers, surfactants and other excipients do? What are their main
physicochemical and colloidal properties and how can I utilize them?
• What are the possible toxicological aspects of the formulation? Is the drug content or
polymer concentration below a safe level?
• To what extent can I optimize the formulation and can I perform a scaling up?
• What are the drug product quality criteria (e.g., purity, sterility) to be used in clinical
settings or to place them on market?
• What container closure system will be used and can the formulation adapt to that?
• What else can the formulation be used for besides my target?
The list of questions could go further based on the research project itself, but quality
management tools such as an establishment of an Ishikawa diagram or mind map are
encouraged to be utilized for selecting the QTPP elements [36].
3.3. Regulatory Reflections
The European Medicines Agency (EMA) published a joint MHLW/EMA reflection
paper on the development of block copolymer micelle medicinal products, which contains
aspects to take into consideration when applying QbD as well [21]. It is supplemented
by the general ICH specifications, e.g., the guidelines of safety pharmacology studies for
human pharmaceuticals (ICH S7A) [37] and the general development and manufacture
of drug substances (ICH Q11) [38]. There are multiple factors that should be taken into
account: first, the description and composition which are related to the later described
CQA and CMA elements. Such factors are the content of the block copolymer and the
active substance in the product, the composition and the polymer’s material attributes,
followed by the quality characterization of the product. Typical examples are the impu-
rity profile, the micelle size, morphology, surface properties, drug loading and in vitro
release/permeability profile, which can be generally measured to all polymeric micelle
product. The joint paper also states that the stability of the block copolymer micelle prod-
ucts should be based on the ICH Q1A(R2) [39] guideline and for the ones containing
biological or biotechnological entities, the ICH Q5C can be applied [40]. For example,
if the stability is included in the QTPP profile of the product, it should be more specific
depending on the manufacturer’s goal—whether it should be physically and/or chemically
stable—which is more important or, in other words, based on the material properties of the
building agents which have the higher risk value. Non-clinical pharmacokinetics should
include relevant measurements of the release and permeability profile of the product com-
plemented by thorough active substance and micelle-forming polymer metabolite screening
using biorelevant mediums (maybe organs and/or tissues). When applicable, safety phar-
macology studies should be conducted in accordance with ICH M3(R2), ICH S7A and ICH
S7B [37,41,42] with toxicological studies based on ICH S4, ICH S6(R1) and ICH S9 [43–45].
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The ICH M3(R2) guidelines also define the starting dose for first-in-human studies. By
keeping in mind this short summary and the knowledge of the specific guidelines, the
CQA and CMA elements were collected in the next step.
3.4. Collection of CQAs for Polymeric Micelle Development
CQAs include those elements that define the quality of our main objectives, the physi-
cal, chemical or microbiological characteristics required to achieve the optimal formulation.
During screening processes, two main things need to be determined or examined first:
the nature of the polymeric micelle forming copolymer and the type of polymeric micelle.
Copolymers can differ in the constitution of monomers and the sensitivity towards en-
vironmental changes. A distinction can be made between copolymers consisting of two
block and those consisting of three blocks, the latter of which can be composed of two
or three different monomers. Graft copolymers are considered to contain chain branches
allowing a more diverse structure [46]. Innovative copolymers are already able to respond
to stimuli by altering the tertiary or quaternary structure of the polymer. Such a stimulus
can be, for example, pH, temperature, ionic strength or even binding to an immunological
element [47]. The arrangement of conventional polymeric micelles is as follows: in a polar
liquid medium, the hydrophilic side chain is solubilized to the outside world, while the
hydrophobic moiety keeps the drug molecularly dispersed. The inverse of this can be also
distinguished when talking about a reverse micelle. Mixed micelles are polymeric micelles
in the construction of which several copolymers play a role. The polymer side chains can
take various forms, depending on the material properties, such as a flower-like micelle,
unimolecular star micelle or unimolecular dendritic micelle. In the hydrophobic core of a
polymeric micelle, several compartments can be formed, mainly with oily substances, in
which case, it is a multicompartment micelle [46]. Morphology of the polymeric micelles
are influenced by the dosage form (e.g., they are incorporated into a hydrogel or just a
colloidal solution) and whether surface modifications have been formulated on the surface
of the outer shell. These modifications all have the same aim: to improve or control the
pharmacokinetic profile of the drug release from the carrier [48,49].
Among the CQAs, the factors describing the particle characteristics of the polymeric
micelles are included. Such factors are: particle size, polydispersity index, encapsulation
efficiency (EE%), drug loading (DL%) and zeta potential. These, combined with polarity
and the definition of wetting parameters, are import elements of optimization. The average
particle size of polymeric micelles is between 20 and 200 nm, which is influenced by the
properties of the building copolymers and the API itself. A particle size distribution is
claimed to be optimal if it is below 0.300. Both the EE% and the DL% are strongly related
to the material properties, the extent of which is determined by the quantitative and qual-
itative features of the polymer. As the hydrophilic side chains are oriented towards the
outer surface after encapsulation of the API, the values of the contact angles to water will
decrease, while those to hydrophobic materials will increase. This leads to increased polar-
ity, which is closely related to water solubility and thus also to dissolution parameters [50].
These factors are the ones that most often form part of the design of experiment (DoE) as
to be optimized. Optimization can be performed by factorial experimental designs, e.g.,
Box–Behnken design, central composite design, Plackett Burman design or the traditional
2x DoE experiments. Nowadays, the creation of neural experimental design networks
is also of key importance, as it is able to study the interactions between factors more
broadly [51,52].
Further investigable CQAs include quantitative parameters related to the permeability
of a carrier, for example flux, permeability coefficient (Kp) or to the drug release, e.g.,
whether a specific kinetic model can be fitted to the dissolution curve or not. Sterility
and stability are included as CQAs if they are of high significance, but the same variables
are taken into account as they were QTPPs. The possible CQAs of polymeric micelles
are summarized in Table 2. Choosing the proper CQA elements for the desired product
depends on the later collected material attributes as well and they should not be considered
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equally potent and relevant to the development process; these differences should be
highlighted and calculated later during an RA.




diblock copolymer (A–B type)
triblock copolymer (A–B–A type)
triblock copolymer (A–B–C type)
graft copolymer
stimuli-sensitive copolymer











polyethylene glycole (PEG) conjugates
(monoclonal) antibodies
peptids, lipids, carbohydrates











API content based on patient, administration route or indiciation
permeability rate based on aim, described with flux or Kp
dissolution rate based on aim
drug release profile kinetic or non-kinetic following
sterility if needed
stability same variables as in QTPPs
3.5. Collection of CPPs and CMAs for Polymeric Micelle Development
The precise definition of the CPP and CMA elements helps in the DoE process as these
are the fundamental factors in getting from the raw material to the nanoDDS. In the case of
polymeric micelles, the preparation can always start or end in a liquid medium, where four
main factors are distinguished: the copolymer, the API, the solvent(s) and any excipients
added. The general CMA factors are presented in Table 3.
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Table 3. Systematic collection of feasible CMA elements for the development of polymeric mi-
celle nanoDDSs.
























Several methods have been developed for the production of polymeric micelles.
Direct dissolution method is commonly used when the micelle-forming copolymers have
relatively high water solubility. The API and the copolymer are directly dissolved in an
aqueous media associated with stirring, heating and/or sonication in order to form the
drug-loaded polymeric micelles [53]. Thus, micelle formation happens by the dehydration
of the core forming blocks. The dialysis method is for copolymers with low water solubility;
therefore, organic solvents are used in this method. During the preparation, the API and
the copolymer(s) are dissolved in a common organic solvent and they are subsequently
dialyzed against water. This triggers the micelle formation besides washing away residual
organic solvents from the formed polymeric micelle solution [54]. Oily substances can be
used in the preparation, when the API is miscible or soluble in the oil phase. With constant
mixing, polymeric micelles can form in the aqueous phase of the emulsion, but this method
needs many after cleaning processes [55]. The freeze-drying method is associated with
dimethylacetamide or tert-butanol as organic (co-)solvents because of their high vapor
pressure offering rapid sublimation. After dissolving the API in the organic solvent-water
mixture, a freeze-dried cake of polymeric micelles can be achieved which demonstrates
adequate shelf-life with high water dispersibility [56]. The thin film method is a production
method based on complete solvent evaporation, where the drug and polymer system
dissolved in any solvent (mixture) is recovered in the form of a thin film. It is then followed
by hydration in water (or water-based buffer) and depending on the properties of the
polymer, the process can also be followed by ultrasonication, mixing or even filtration,
just like in the production process for liposomes [8,9]. Possible CPP elements and specific
CMAs associated with each production method are collected in Table 4.
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Table 4. Systematic collection of feasible CPP elements for the different preparation methods of
polymeric micelles.

































thin film method/vacuum evaporation
temperature






3.6. Risk Assessment on Critical Quality Attributes
Based on the quality by design methodology, two risk assessment have to be per-
formed: between QTPPs and CQAs, where the severity score of the CQAs is obtained,
and between the CQAs and CPPs/CMAs, where the severity score of the latter can also
be calculated. The severity scores of CQAs in declining order are presented on the Pareto
diagram in Figure 2.
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The material properties of the polymer, the API, the solvents and other excipients
were taken into account in the risk assessment. The factors also cover data from the basic
physicochemical property to the safety elements. Safety numbers are presented with
low severity scores, as dosage strength is highly controllable, making it able to present a
polymeric micelle formulation with less chance of toxicity. The polymer, API and solvent
properties cannot be ever excluded, as they are severely influence the formation of the
nanoparticles. On Figure 4, Pareto diagrams of CPPs/CMAs for each preparation method
are presented.
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It can be seen that quite different factors also appear on the different charts in de-
creasing order of severity score. Although the production methods may be based on a
similar principle, it is important to assess the risks associated with each sub-step as part
of the manufacturing process. Furthermore, the risk factors that may arise mainly from
human negligence, e.g., measurement error, incorrect data setting or risks due to manufac-
turer/measuring instrument failure, e.g., broken device faulty circuit, are not presented as
they are constant among the possible risk factors in the manufacturing process.
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3.8. Case Example for the Thought Process of Applying QbD-Based RA
In the rapidly evolving field of nanotechnology and the manufacturing of polymer-
based nanocarriers, the assigned severity scores can vary based on many material and
target quality-based factors. It can be claimed that there is an antipsychotic compound
which has low water solubility and inefficient permeability can be experienced from the
intestinal tract from previously formulated solid tablet formulations. Based on this sentence
alone, many QTPP elements can be already determined: What is the marketed/clinically
efficient dosage strength of the API? What other administration route can I exploit? What
is the target population of this API? What is the major indication field of this substance?
What physicochemical and pharmacokinetic attributes do I want to improve on? The next
step is to make adjustments to this based on your goal: instead of the adult population,
the target population should be children; therefore, my target dosage strength must be
lowered accordingly to pharmacokinetic parameters. A novel article was found during
the knowledge space development phase of my research where the suspension form of
this API delivered by the nasal route showed higher brain concentrations, resulting in
more advanced therapeutic effect in the major indication. Then, all process and material
parameters should be taken into account, for example, in the research laboratory, we have
a deep knowledge on freeze-drying production method for polymeric nanocarriers, so
that should be the chosen formulation method and there are suitable micelle-forming
copolymers which are able to decrease the particle size of APIs below 100 nm.
Gathering all this information, we can now determine the QTPP profile of the desired
product, meaning we want to develop a API-loaded mixed polymeric micelle, which:
• has the micellar size less than a 100 nm in monodisperse distribution (QTPP: particle
characteristics);
• is suitable for the treatment of psychotic episodes (QTPP: indication);
• can be applied for children (QTPP: target population);
• is administered intranasally (QTPP: administration route);
• in the form of a nasal spray (QTPP: dosage form);
• in half of the currently marketed drug strength (QTPP: dosage strength);
• allowing higher brain concentrations (QTPP: site of activity),
• with sustained drug release (QTPP: drug release profile);
• and enhanced permeability across the nasal mucosa (QTPP: permeability profile).
After the collection of QTPPs, the next step is to gather all the possible CQAs relevant
to these targets: mixed polymer types, particle size and polydispersity index, pH, viscosity,
mucoadhesivity, osmolality, dissolution rate, permeability rate, drug content uniformity,
etc., and investigate the effect on the QTPPs in a 3-scale interdependence rating followed by
the calculation of the severity scores using any QbD-modelling software. The same applies
to the CMAs and CPPs: for example, each mixed micelle forming polymer concentration,
solvent volume, freeze-drying temperatures, cryoprotectant concentration and reconstitu-
tion. After the calculation of the severity scores, the following results were observed:
• The highest CQA severity scores were for the particle size, permeability rate and
dissolution rate (based on the material attributes of the to be used excipients, polymers
and the desired target of the product);
• The highest CMA/CPP severity scores were for the polymer ratios, the solvent volume
and the cryoprotectant concentration (based on the establishment of knowledge about
what does the equipment provided to us are able to perform and prior optimization
processes for polymeric nanocarriers).
To continue next to set up a design of experiment, many aspects can be followed.
One is to make one high-severity risk factor at a constant level or the other is to make it a
dependent factor to our factorial design. We chose the cryoprotectant concentration to be
fixed at 5 % w/w and, furthermore, we investigate the effect of the polymer ratios and the
solvent volume on the independent factors: particle size, dissolution and permeability rate
during a factorial design of our choosing.
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3.9. Optimization Techniques of Polymeric Micelles via QbD-Based Design of Experiment (DoE)
One of the cornerstones of the QbD approach is that, at the end of the risk assessment,
an extensive formulation optimization follows. This is most often done by setting up a
factorial or neural experimental design, after which the design space is set up with proper
statistical evaluation and then the formulation is characterized to validate it. If a quality
defect is discovered during the life course of the formulation, then adjustments but be made.
One good example of applying QbD as a part of the DoE set-up is the work of Khurana
et al., where a 13-run central composite design was used to optimize resveratrol-loaded
polymeric micelles [57]. Based on their risk assessment, the selected CQA elements with the
highest risk severity were micellar incorporation efficiency (MIE), the particle size and the
skin deposition potential. The effect of polymer ratio and the API content were investigated
on these CQAs and a response analysis were carried out through polynomial equation. By
plotting the surface plots, the optimized polymer to API ratio was found and satisfactory
results were obtained: the observed MIE was 93.45% with a particle size of 142.67 nm and
skin deposition of 51.63% which all meet the requirements of a polymer-based nanoDDS
for topical drug delivery supplemented by advanced in vivo pharmacokinetics. Another
great example of QbD-based DoE is the work of Lohan et al., where after the construction of
an Ishikawa fish-bone diagram containing the factors influencing the galantamine-loaded
mixed micelle formulation, a 7-factor 8-run Taguchi orthogonal array design was employed
aiming to reveal the potential impact of various material attributes on product quality [58].
After the screening, they investigated the effect of DSPE-PEG 2000 and soy lecithin on
the particle characteristics and drug release in a 13-run central composite design, as well
as with 5 parallel measurements. A great tool to decrease the severity of the risk factors
was applied by them: keeping the high-risk valued ethanol concentration at a fixed ratio,
meaning that the optimized formulation should be matched with this factor. By the end of
the optimization, the desirability functions were compared to the investigated parameters
and a nanosized mixed micellar system was developed with a particle size of 175 nm, a
zeta potential of −18 mV and a dissolution efficiency of 86%. In our previous work, the
optimization of Meloxicam-loaded polymeric micelles via RA-based Box–Behnken factorial
design was performed and a one-way ANOVA statistical analysis of the results was applied.
The effect of the ethanol and sodium-hydroxide volume and the polymer concentration
was investigated on particle size and particle size distribution with end results of 111.6 nm
and a PdI of 0.114, allowing proper basis for nasal drug delivery [9]. In addition to these
examples, many factorial/neural design studies are there in the literature for polymeric
micelles; however, the lack of pre-optimization risk screening can be observed. That is
why it is encouraging to use the demonstrated knowledge space development and risk
assessment, along with statistical analysis of your choosing, so the micellar formulations
can be matched to quality management as well.
4. Discussion
Through mandatory steps of quality by design, this article has collected and evalu-
ated the factors that influence the successful development of a polymeric micelle based
nanocarrier system. The QTPP elements, as proven, depend on the purpose; however, it is
important to incorporate the mandatory elements of the ICH guidelines when setting up
the pilot design. For polymeric micelles, as promising nanotherapeutics, this is not an easy
task, as new indications and therapeutic possibilities may occur due to particle size reduc-
tion and modification of the administration route, leading to a different pharmacokinetic
profile. The CQA, CPP and CMA elements were collected in their entirety to characterize a
general formulation based on literature. These parameters are those that affect the quality
of the product from the beginning of the manufacturing process to the patient’s use.
During the course of our research, we first collected the QTPP, CQA, CMA and CPP
factors that influence the quality of a polymeric micelle formulation. Amongst QTPPs, it can
be seen that it can range from general application principles to the extent of physicochemical
and pharmacokinetic factors. It is important to see that QTPP elements are those without
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which risk assessment would not be possible. A separate risk assessment process is
required for each polymeric micelle formulation, regardless of whether it contains an active
substance or it concerns a development of a new polymeric carrier system able to form
micelles. In the risk assessment with the CQA, CPP and CMA elements, we shed light on
which posed the greatest risk for a general nanoformulation. Of course, a researcher has
to decide for themself which factors are relevant to the production process and product
quality chosen, so we performed the analysis for several production methods common
amongst developers. The risk assessment of R&D processes is of particular importance for
nanocarriers. Greater emphasis should also be placed on the basic properties of polymers
and the active substance, as well as on the steps in the manufacturing process. The
optimization of the particle characteristics also depends, crucially, on the nature of the
building polymer and the manufacturing process.
Although the main points presented on the tables and figures are just fragments of the
evidence presented in many articles and development processes, the systemic collection of
all the influencing factors as data is the novelty of this current work. To demonstrate that
the CMAs and CPPs parallelly improve the transparency between these parameters and
their relation between CQA elements, in Tables 1–4, the general collection of influencing
factors can be seen, followed by an RA process as seen on Figures 2–4. The Pareto charts
on Figures show the theoretical ranking of the severity of the influencing factors as part of
an initial general RA.
This presented work can fit well into the research area of polymeric micelles as it is an
extension of the previous knowledge acquired by prior results. QbD is also recommended
by regulatory authorities and encourage researchers to build the process of nanocarriers
into their development.
5. Conclusions
The novelty of the work was that polymeric micelles were systematically evaluated
on the basis of knowledge and risk, as these nanotherapeutics require a special regulatory
environment. The quality by design methodology offered a thoroughly quality-focused
assurance system, which proved to be useful in the case of polymeric micelles. As an
encouragement, it is recommended that all researchers use the previous literature and
evaluate the significant factors under a risk assessment process, resulting in a more focused
design of experiment. Later, knowledge of these factors provides an important basis for
quality and process control and allows for an easier to manage, correctable manufactur-
ing process.
Author Contributions: Conceptualization, B.S. and I.C.; methodology, B.S., G.K. and I.C.; software,
B.S.; validation, G.K. and I.C.; formal analysis, G.K.; investigation, B.S., G.K. and I.C.; resources, I.C.;
data curation, B.S., G.K. and I.C.; writing—original draft preparation, B.S. and G.K.; writing—review
and editing, I.C.; visualization, B.S.; supervision, G.K. and I.C.; project administration, B.S., G.K. and
I.C.; funding acquisition, G.K. and I.C. All authors have read and agreed to the published version of
the manuscript.
Funding: The publication was funded by the University of Szeged Open Access Fund (FundRef,
Grant No. 5232).
Institutional Review Board Statement: Not applicable.
Informed Consent Statement: Not applicable.
Data Availability Statement: The data presented in this study are available on request from the
corresponding author.
Acknowledgments: This work was supported by EFOP 3.6.3-VEKOP-16-2017-00009, National Re-
search, Development and Innovation Office, Hungary (GINOP-2.3.2-15-2016-00060) and Ministry of
Human Capacities, Hungary grant, TKP-2020 projects.
Conflicts of Interest: The authors declare no conflict of interest.
Pharmaceutics 2021, 13, 702 16 of 17
References
1. Khanna, I. Drug discovery in pharmaceutical industry: Productivity challenges and trends. Drug Discov. Today 2012, 17, 1088–1102.
[CrossRef] [PubMed]
2. Schweizer, L.; Dingermann, T. Introduction: Trends and Developments in the Pharmaceutical and Life Sciences Industry.
In Advances in Pharma Business Management and Research: Volume 1; Schweizer, L., Dingermann, T., Russe, O.Q., Jansen, C., Eds.;
Springer International Publishing: Cham, Switzerland, 2020; pp. 1–5, ISBN 978-3-030-35918-8.
3. Patil, A.S.; Pethe, A.M. Quality by design (QbD): A new concept for development of quality pharmaceuticals. Int. J. Pharm.
Qual. Assur. 2013, 4, 13–19.
4. Yu, L.X.; Amidon, G.; Khan, M.A.; Hoag, S.W.; Polli, J.; Raju, G.K.; Woodcock, J. Understanding pharmaceutical quality by design.
AAPS J. 2014, 16, 771–783. [CrossRef]
5. Li, J.; Qiao, Y.; Wu, Z. Nanosystem trends in drug delivery using quality-by-design concept. J. Control. Release 2017, 256, 9–18.
[CrossRef] [PubMed]
6. Xu, X.; Khan, M.A.; Burgess, D.J. A quality by design (QbD) case study on liposomes containing hydrophilic API: I. Formulation,
processing design and risk assessment. Int. J. Pharm. 2011, 419, 52–59. [CrossRef]
7. Rawal, M.; Singh, A.; Amiji, M.M. Quality-by-Design Concepts to Improve Nanotechnology-Based Drug Development.
Pharm. Res. 2019, 36. [CrossRef] [PubMed]
8. Németh, Z.; Pallagi, E.; Dobó, D.G.; Csóka, I. A proposed methodology for a risk assessment-based liposome development
process. Pharmaceutics 2020, 12, 1164. [CrossRef]
9. Sipos, B.; Szabó-Révész, P.; Csóka, I.; Pallagi, E.; Dobó, D.G.; Bélteky, P.; Kónya, Z.; Deák, Á.; Janovák, L.; Katona, G. Quality by design
based formulation study of meloxicam-loaded polymeric micelles for intranasal administration. Pharmaceutics 2020, 12, 697. [CrossRef]
10. Katona, G.; Balogh, G.T.; Dargó, G.; Gáspár, R.; Márki, Á.; Ducza, E.; Sztojkov-Ivanov, A.; Tömösi, F.; Kecskeméti, G.; Janáky, T.;
et al. Development of meloxicam-human serum albumin nanoparticles for nose-to-brain delivery via application of a quality by
design approach. Pharmaceutics 2020, 12, 97. [CrossRef]
11. Warheit, D.B. How meaningful are the results of nanotoxicity studies in the absence of adequate material characterization?
Toxicol. Sci. 2008, 101, 183–185. [CrossRef]
12. Fischer, H.C.; Chan, W.C. Nanotoxicity: The growing need for in vivo study. Curr. Opin. Biotechnol. 2007, 18, 565–571. [CrossRef]
[PubMed]
13. Miyata, K.; Christie, R.J.; Kataoka, K. Polymeric micelles for nano-scale drug delivery. React. Funct. Polym. 2011, 71, 227–234.
[CrossRef]
14. Lu, Y.; Park, K. Polymeric micelles and alternative nanonized delivery vehicles for poorly soluble drugs. Int. J. Pharm. 2013, 453,
198–214. [CrossRef] [PubMed]
15. Owen, S.C.; Chan, D.P.Y.; Shoichet, M.S. Polymeric micelle stability. Nano Today 2012, 7, 53–65. [CrossRef]
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